Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS
· Delayed Price · Currency is USD
14.80
0.00 (0.00%)
At close: Mar 7, 2025
TEVJF Revenue
In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth. Teva Pharmaceutical Industries had revenue of $4.23B in the quarter ending December 31, 2024, a decrease of -5.12%.
Revenue
16.54B
Revenue Growth
+4.40%
P/S Ratio
n/a
Revenue / Employee
475.55K
Employees
35,686
Market Cap
18.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
Teva Pharmaceutical Industries News
- 6 days ago - Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds - Seeking Alpha
- 8 days ago - Deckers Outdoor Corp (DECK) Unveils Teva's Spring-Summer 2025 Collection - GuruFocus
- 9 days ago - Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March - GlobeNewsWire
- 12 days ago - Teva Pharmaceutical: A Risky Bet With Potential Upside - Seeking Alpha
- 13 days ago - 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals - GlobeNewsWire
- 15 days ago - FDA accepts Teva's application for Uzedy for bipolar I disorder - Seeking Alpha
- 15 days ago - Teva Pharmaceutical's UZEDY sNDA Accepted by FDA for Bipolar I Disorder Treatment - GuruFocus
- 15 days ago - Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder - GlobeNewsWire